NEOG Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Recurring Consumables And Cross-sellingNeogen's business is anchored in high-frequency consumables and test kits that customers repurchase as part of compliance and quality programs. That consumables pull-through plus instrument placements and cross-selling across product lines creates durable, repeatable revenue and margin stability over time.
Improving Cash GenerationThe shift to positive trailing‑12‑month operating and free cash flow materially strengthens financial flexibility. Durable cash generation supports R&D and transformation spend, funds debt reduction plans, and reduces the need for dilutive financing—though cash quality must be proven across cycles.
Food Safety Growth And Margin ExpansionFood Safety’s above‑trend growth and a near‑50% gross margin indicate a structurally profitable core franchise. Petrifilm manufacturing and innovation milestones (new SKUs, pilot line) can drive sustained consumables pull‑through, higher mix of proprietary products, and durable margin improvement over multiple quarters.
Bears Say
Recurring Net Losses And Weak Operating ResultsPersistent negative operating results and intermittent large GAAP losses erode retained earnings and limit the company's ability to self‑fund growth. Until operating profitability consistently returns, ROE and reinvestment capacity remain constrained, forcing reliance on cash or asset sales to meet strategic goals.
Operational Complexity Of Petrifilm TransitionThe multi‑quarter manufacturing and SKU transition increases execution risk and could trigger inventory write‑offs, supply disruptions or customer service setbacks. Such operational complexity can compress near‑term margins and delay the anticipated revenue and consumables pull‑through benefits from the Petrifilm program.
Genomics Divestiture Regulatory UncertaintyProceeds from the genomics sale are earmarked to materially reduce leverage and fund strategy. A second‑phase regulatory review creates timing and outcome uncertainty; a delay or adverse outcome would keep leverage high, constrain capital allocation, and force alternative financing or slower investment pacing.
Neogen News
NEOG FAQ
What was Neogen Corp’s price range in the past 12 months?
Currently, no data Available
What is Neogen Corp’s market cap?
Neogen Corp’s market cap is $44.14B.
When is Neogen Corp’s upcoming earnings report date?
Neogen Corp’s upcoming earnings report date is Oct 08, 2026 which is in 53 days.
How were Neogen Corp’s earnings last quarter?
Neogen Corp released its earnings results on Jul 30, 2026. The company reported $1.551 earnings per share for the quarter, beating the consensus estimate of $0.983 by $0.569.
Is Neogen Corp overvalued?
According to Wall Street analysts Neogen Corp’s price is currently Undervalued.
Does Neogen Corp pay dividends?
Neogen Corp does not currently pay dividends.
What is Neogen Corp’s EPS estimate?
Neogen Corp’s EPS estimate is 0.86.
How many shares outstanding does Neogen Corp have?
Neogen Corp has 218,056,020 shares outstanding.
What happened to Neogen Corp’s price movement after its last earnings report?
Neogen Corp reported an EPS of $1.551 in its last earnings report, beating expectations of $0.983. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Neogen Corp?
Currently, no hedge funds are holding shares in MX:NEOG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neogen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$213.29 (― Upside)
$213.29 (― Upside)
Blogger Sentiment
Bullish
MX:NEOG Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $74.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
107.74%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.63%
Trailing 12-Months
Company Description
Neogen Corp
Neogen Corporation, including its affiliated companies, is a global leader in creating, manufacturing, and distributing a wide range of products crucial for maintaining food quality and animal health. The enterprise is structured into two primary divisions: Food Safety and Animal Safety. The Food Safety segment delivers advanced diagnostic test kits and associated solutions to identify detrimental or unintended contaminants in food and animal feed. This extensive detection capability covers threats such as foodborne pathogens, spoilage-causing organisms, naturally occurring toxins, food allergens, genetically modified ingredients, ruminant by-products, specific meat identification, residual drugs and pesticides, and overall sanitation issues. A key product is the AccuPoint Advanced rapid sanitation test, which quickly spots adenosine triphosphate (ATP), indicating the presence of living cells, to verify cleanliness. Customers for this segment are diverse, encompassing producers and processors of food and feed, grain operations, manufacturers of processed foods like cookies, crackers, candy, and ice cream, as well as those handling meat, poultry, seafood, fruits, vegetables, and dairy. It also serves laboratories and producers of pharmaceuticals, cosmetics, and veterinary vaccines. The Animal Safety division provides a comprehensive portfolio for the animal health market. Offerings include veterinary instruments, pharmaceuticals, vaccines, topical medications, parasiticides, diagnostic products, rodenticides, cleaning agents, disinfectants, insecticides, and genomics testing services. This segment also supplies specialized products for researchers investigating biologically active substances. Its immunoassay test kits are vital for detecting illicit and therapeutic drugs in farm and racing animals, identifying drug residues in meat and meat products, and assisting in human forensic toxicology drug screenings. Moreover, products from this division are instrumental in upholding hygienic conditions and minimizing the risks posed by bacteria, fungi, and viruses. Neogen Corporation was established in 1981 and is headquartered in Lansing, Michigan.
NEOG Company Deck
NEOG Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a constructive, execution-focused tone: management reported clear operational improvements (stronger Food Safety growth, Animal Safety recovery, inventory reduction, margin expansion and record quarterly cash flow) and important milestones on Petrifilm and R&D. At the same time, the company is deliberately accelerating investments (R&D, commercial transformation, technology) and carrying meaningful leverage with a pending genomics divestiture subject to regulatory review. Near-term margins and guidance reflect these investments and macro/currency headwinds, but the strategic actions and early results point to a credible path to stronger, more profitable growth over the medium term.View all MX:NEOG earnings summaries